Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

Li Jiang(Sichuan Cancer Hospital), Yongsheng Wang(Lanzhou University of Technology)

Scientific Reports

March 6, 2019

10.1038/s41598-018-38068-3

Cited by 45

Related Papers

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

|BMJ|2023|82

The PI3K/Akt/mTOR Pathway: Immuno-Metabolic Orchestration in IR/MASH-Associated Hepatocellular Carcinoma

|International Journal of Biological Sciences|2025|12